Melanocortin Receptor Peptides Side Effects: Safety Signals and Warnings
Melanocortin Receptor Peptides safety concerns are compound-specific. The main listed side effects are Nausea (most common, 40% of patients), Flushing, and Injection site reactions. The main warning signals are Bremelanotide is contraindicated in uncontrolled hypertension, Transient blood pressure elevations of 6-12 mmHg reported, and Nausea is the primary tolerability concern - tends to improve with repeat use.
Direct Answer
Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference.
- Evidence grade
- Level D
- Research status
- Early Research
- Category
- Sexual Health
- Evidence context
- Melanocortin receptor pharmacology research, receptor subtype selectivity studies
Reported Side Effects
- Nausea (most common, 40% of patients)
- Flushing
- Injection site reactions
- Headache
- Transient blood pressure increase
- Skin hyperpigmentation with repeated use
- Darkening of gums and face
Warnings
- Bremelanotide is contraindicated in uncontrolled hypertension
- Transient blood pressure elevations of 6-12 mmHg reported
- Nausea is the primary tolerability concern - tends to improve with repeat use
- Focal skin hyperpigmentation may occur with chronic use and may not resolve after discontinuation
- Not recommended for use with naltrexone (potential drug interaction)
Known or Plausible Interactions
- Naltrexone (may diminish bremelanotide effectiveness)
- Antihypertensive medications (monitor for additive or opposing blood pressure effects)
- PDE5 inhibitors (no formal interaction study but theoretical additive cardiovascular effects)
Regulatory Context
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Setmelanotide (Imcivree) is FDA-approved for rare genetic obesity disorders. Other melanocortin peptides remain investigational. Prescription only. Not controlled substances.
Evidence Snapshot
| Evidence grade | Level D |
|---|---|
| Research status | Early Research |
| Best supported outcomes | Female Sexual Desire (Bremelanotide) (Level A), MC4R-Based Obesity Research (Level C), and Anti-Inflammatory (MC System) (Level D) |
| Primary citation count | 3 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Melanocortin Receptor Peptides?
Melanocortin Receptor Peptides safety concerns are compound-specific. The main listed side effects are Nausea (most common, 40% of patients), Flushing, and Injection site reactions. The main warning signals are Bremelanotide is contraindicated in uncontrolled hypertension, Transient blood pressure elevations of 6-12 mmHg reported, and Nausea is the primary tolerability concern - tends to improve with repeat use.
What is the evidence level for Melanocortin Receptor Peptides?
Melanocortin Receptor Peptides is rated Level D. Its current research status is Early Research.
What is Melanocortin Receptor Peptides best known for?
Melanocortin receptor pharmacology research, receptor subtype selectivity studies.
Where can I read the full Melanocortin Receptor Peptides evidence review?
The full evidence review is available at https://examinepeptides.com/library/melanocortin-peptides.
Related Guides
How to Cite This Page
ExaminePeptides. "Melanocortin Receptor Peptides Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/melanocortin-peptides-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.